Dr. Berdeja Discusses Response to CAR T-Cell Therapy bb2121

Video

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses response to the chimeric antigen receptor (CAR) T-cell therapy bb2121 in patients with multiple myeloma.

In a study of 21 patients, bb2121 was generally well tolerated with an objective response rate of 94% and a partial response rate or better of 89%. The first dose level was therapeutic, so 3 patients had a transient response and progressed very quickly, said Berdeja. After that, all but 1 patient had a response that was durable at the 150 mg dose.

Overall response in patients treated at the therapeutic dose levels was 94% with a 56% complete response rate, and the responses continue to improve with time, Berdeja adds. The therapy is working so quickly in fact, that it is inducing a complex assessment in myeloma because the tumor cells are being killed, but then the pair of proteins that are required to become negative are lagging, Berdeja explains. Additionally, minimal residual disease negativity is being seen in patients.

The FDA granted bb2121 a breakthrough therapy designation in November of 2017, based on preliminary clinical data from the ongoing phase I CRB-401 study.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.